Could a common arthritis drug tame a rare, fatal blood vessel disease?

This study tests whether baricitinib, a drug already approved for arthritis, can help people with Kohlmeier-Degos (KD) disease that affects the brain and spine. KD causes inflammation and blood clots that damage small blood vessels, and there is currently no treatment. The trial will enroll 12 adults who will take baricitinib daily for 24 weeks, and researchers will use MRI scans to see if existing lesions stabilize and no new ones appear.